Regulatory T cells: What role do they play in antitumor immunity in patients with head and neck cancer?
暂无分享,去创建一个
J. Myers | J. Greenman | N. Stafford | O. Alhamarneh | Shoba Amarnath | Jeffrey N. Myers | Nicholas D. Stafford
[1] J. Greenman,et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. , 2007, The Journal of laryngology and otology.
[2] T. Whiteside,et al. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck , 2007, Head & neck.
[3] T. Whiteside,et al. Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1 , 2007, The Journal of Immunology.
[4] N. Hayashi,et al. Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell‐mediated induction of CD4+ CD25+ T cells with PD‐1‐dependent regulatory activities , 2007, Immunology.
[5] H. Weiner,et al. Th3 Cells in Peripheral Tolerance. I. Induction of Foxp3-Positive Regulatory T Cells by Th3 Cells Derived from TGF-β T Cell-Transgenic Mice1 , 2007, The Journal of Immunology.
[6] A. Banham. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. , 2006, Trends in immunology.
[7] Emili Montserrat,et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.
[8] H. Fujii,et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers , 2006, Cancer Immunology, Immunotherapy.
[9] H. Weiner,et al. TGF-β-Mediated Suppression by CD4+CD25+ T Cells Is Facilitated by CTLA-4 Signaling , 2006, The Journal of Immunology.
[10] Z. Tian,et al. The regulatory effect of natural killer cells: do "NK-reg cells" exist? , 2006, Cellular & molecular immunology.
[11] W. Zou,et al. Regulatory T-cell compartmentalization and trafficking. , 2006, Blood.
[12] T. Gingeras,et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.
[13] G. Zhu,et al. Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells1 , 2006, The Journal of Immunology.
[14] M. Young,et al. Protective mechanisms of head and neck squamous cell carcinomas from immune assault , 2006, Head & neck.
[15] W. Zou. Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.
[16] T. Whiteside,et al. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.
[17] T. Whiteside,et al. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck , 2006, Cancer Immunology, Immunotherapy.
[18] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[19] T. Curiel,et al. Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential , 2005, American journal of reproductive immunology.
[20] T. Nomura,et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells , 2005, The Journal of experimental medicine.
[21] D. Linehan,et al. CD25+CD4+ regulatory T-cells in cancer , 2005, Immunologic research.
[22] R. Ferris,et al. Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites , 2005, Cancer Immunology, Immunotherapy.
[23] C. N. Coleman,et al. The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors , 2005, Clinical Cancer Research.
[24] S. Lira,et al. Lymph Node Occupancy Is Required for the Peripheral Development of Alloantigen-Specific Foxp3+ Regulatory T Cells1 , 2005, The Journal of Immunology.
[25] K. Bartels,et al. A local enrichment of regulatory T cells within the tumor tissue might suppress an effective anti-tumor T cell response in patients with head and neck cancer , 2005 .
[26] S. Chattopadhyay,et al. Regulatory T cells and tumor immunity , 2005, Cancer Immunology, Immunotherapy.
[27] S. Sakaguchi. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.
[28] J. Schlom,et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.
[29] R. Schwartz,et al. Natural regulatory T cells and self-tolerance , 2005, Nature Immunology.
[30] H. Boehmer,et al. Mechanisms of suppression by suppressor T cells , 2005, Nature Immunology.
[31] C. Baecher-Allan,et al. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. , 2005, Clinical immunology.
[32] Giovanna Roncador,et al. Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells , 2005, Clinical Cancer Research.
[33] David C. Gondek,et al. Cutting Edge: Contact-Mediated Suppression by CD4+CD25+ Regulatory Cells Involves a Granzyme B-Dependent, Perforin-Independent Mechanism1 , 2005, The Journal of Immunology.
[34] R. Bonasio,et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. , 2005, Immunity.
[35] E. Wherry,et al. Bone Marrow Is a Preferred Site for Homeostatic Proliferation of Memory CD8 T Cells , 2005, The Journal of Immunology.
[36] F. Ronchese,et al. Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.
[37] P. Hillsamer,et al. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. , 2004, The Journal of clinical investigation.
[38] Brian Barnett,et al. Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals , 2004, Cancer Research.
[39] J. Bluestone,et al. Distinct roles of CTLA‐4 and TGF‐β in CD4+CD25+ regulatory T cell function , 2004 .
[40] C. Drake,et al. Role of LAG-3 in regulatory T cells. , 2004, Immunity.
[41] S. Rosenberg,et al. Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.
[42] E. Shevach. Regulatory/suppressor T cells in health and disease. , 2004, Arthritis and rheumatism.
[43] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[44] Lieping Chen,et al. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. , 2004, Microbes and infection.
[45] R. Ferris,et al. Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.
[46] T. Whiteside. Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer? , 2004, Cancer Immunology, Immunotherapy.
[47] J. Berzofsky,et al. Immunoregulatory T cells in tumor immunity. , 2004, Current opinion in immunology.
[48] C. Riccardi,et al. Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations , 2004, European journal of immunology.
[49] A. Fattorossi,et al. Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T‐cell receptor Vβ repertoire , 2003, Immunology.
[50] H. Fujii,et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] F. Ramsdell,et al. Foxp3 and natural regulatory T cells: key to a cell lineage? , 2003, Immunity.
[52] L. Klein,et al. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[53] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[54] Thomas Davis,et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[55] J. Longmate,et al. CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model1 , 2003, The Journal of Immunology.
[56] A. Rudensky,et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.
[57] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2003 .
[58] M. Steurer,et al. Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] S. Ferrone,et al. HLA class I antigen loss, tumor immune escape and immune selection. , 2002, Vaccine.
[60] E. Remmerswaal,et al. Proliferation Requirements of Cytomegalovirus-Specific, Effector-Type Human CD8+ T Cells1 , 2002, The Journal of Immunology.
[61] J. Lafaille,et al. Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.
[62] T. Eberlein,et al. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.
[63] Y. Tokura,et al. Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity , 2001, Immunology.
[64] E. Shevach,et al. Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells , 2001, The Journal of Immunology.
[65] M. Salmon,et al. Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis‐prone population , 2001, European journal of immunology.
[66] D. Mason,et al. Human CD4+CD25+ thymocytes and peripheral T cells have immune suppressive activity in vitro , 2001, European journal of immunology.
[67] S. Sakaguchi. Regulatory T cells , 2006, Springer Seminars in Immunopathology.
[68] J. Shimizu,et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.
[69] T. Fujita,et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.
[70] J. Johnson,et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] J. Johnson,et al. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] B. Melichar,et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[73] D. Carbone,et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] M. Young,et al. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer , 1996, International journal of cancer.
[75] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[76] A. Katz,et al. Update on immunology of head and neck cancer. , 1993, The Medical clinics of North America.
[77] R. North,et al. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor , 1980, The Journal of experimental medicine.
[78] R. Ferris,et al. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. , 2005, Advances in oto-rhino-laryngology.
[79] T. Whiteside. Immunobiology of head and neck cancer , 2005, Cancer and Metastasis Reviews.
[80] A. Foussat,et al. A Comparative Study between T Regulatory Type 1 and CD4 CD25 T Cells in the Control of Inflammation , 2003 .
[81] P. Rodriguez,et al. Mechanisms of tumor evasion from the immune response. , 2003, Cancer chemotherapy and biological response modifiers.
[82] I. Melero,et al. CD4 /CD25 Regulatory Cells Inhibit Activation of Tumor-Primed CD4 T Cells with IFN- -Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination , 2003 .
[83] E. Shevach. Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.
[84] B. Wollenberg,et al. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. , 1999, Archives of otolaryngology--head & neck surgery.